These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26202640)

  • 1. Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries.
    Dan YY; Wong JB; Hamid SS; Han KH; Jia JD; Liu CJ; Piratvisuth T; Lok AS; Lim SG
    Hepatol Int; 2014 Jul; 8(3):382-94. PubMed ID: 26202640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reimbursement policies in the Asia-Pacific for chronic hepatitis B.
    Lim SG; Amarapurkar DN; Chan HL; Crawford DH; Gane EJ; Han KH; Ahn SH; Jafri W; Jia J; Kao JH; Lesmana LA; Lesmana CR; Mohamed R; Phiet PH; Piratvisuth T; Sarin SK; Sollarno JD; Eguchi Y; Mahtab MA; Lee KH
    Hepatol Int; 2015 Jan; 9(1):43-51. PubMed ID: 25788378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China.
    Toy M; Hutton DW; So SK
    PLoS One; 2015; 10(11):e0139876. PubMed ID: 26536626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
    Ke W; Zhang C; Liu L; Gao Y; Yao Z; Ye X; Zhou S; Yang Y
    Hepatol Int; 2016 Nov; 10(6):924-936. PubMed ID: 27271357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy.
    Lui YY; Tsoi KK; Wong VW; Kao JH; Hou JL; Teo EK; Mohamed R; Piratvisuth T; Han KH; Mihm U; Wong GL; Chan HL
    Antivir Ther; 2010; 15(2):145-55. PubMed ID: 20386069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of antiviral treatments for HBeAg-positive chronic hepatitis B in Canada.
    He J; Bowen JM; Xie F; Goeree R
    Value Health; 2012; 15(6):894-906. PubMed ID: 22999140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements.
    Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma
    J Gastroenterol Hepatol; 2010 Apr; 25(4):657-63. PubMed ID: 20492323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update.
    Shiha G; Ibrahim A; Helmy A; Sarin SK; Omata M; Kumar A; Bernstien D; Maruyama H; Saraswat V; Chawla Y; Hamid S; Abbas Z; Bedossa P; Sakhuja P; Elmahatab M; Lim SG; Lesmana L; Sollano J; Jia JD; Abbas B; Omar A; Sharma B; Payawal D; Abdallah A; Serwah A; Hamed A; Elsayed A; AbdelMaqsod A; Hassanein T; Ihab A; GHaziuan H; Zein N; Kumar M
    Hepatol Int; 2017 Jan; 11(1):1-30. PubMed ID: 27714681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.
    Bermingham SL; Hughes R; Fenu E; Sawyer LM; Boxall E; T Kennedy P; Dusheiko G; Hill-Cawthorne G; Thomas H
    Value Health; 2015 Sep; 18(6):800-9. PubMed ID: 26409607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014.
    Sarin SK; Kedarisetty CK; Abbas Z; Amarapurkar D; Bihari C; Chan AC; Chawla YK; Dokmeci AK; Garg H; Ghazinyan H; Hamid S; Kim DJ; Komolmit P; Lata S; Lee GH; Lesmana LA; Mahtab M; Maiwall R; Moreau R; Ning Q; Pamecha V; Payawal DA; Rastogi A; Rahman S; Rela M; Saraya A; Samuel D; Saraswat V; Shah S; Shiha G; Sharma BC; Sharma MK; Sharma K; Butt AS; Tan SS; Vashishtha C; Wani ZA; Yuen MF; Yokosuka O;
    Hepatol Int; 2014 Oct; 8(4):453-71. PubMed ID: 26202751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APASL consensus statements and management algorithms for hepatitis C virus infection.
    Omata M; Kanda T; Yu ML; Yokosuka O; Lim SG; Jafri W; Tateishi R; Hamid SS; Chuang WL; Chutaputti A; Wei L; Sollano J; Sarin SK; Kao JH; McCaughan GW
    Hepatol Int; 2012 Apr; 6(2):409-35. PubMed ID: 26201405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.
    Omata M; Kanda T; Wei L; Yu ML; Chuang WL; Ibrahim A; Lesmana CR; Sollano J; Kumar M; Jindal A; Sharma BC; Hamid SS; Dokmeci AK; Al-Mahtab M; McCaughan GW; Wasim J; Crawford DH; Kao JH; Yokosuka O; Lau GK; Sarin SK
    Hepatol Int; 2016 Sep; 10(5):681-701. PubMed ID: 27229718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
    Wu B; Li T; Chen H; Shen J
    Value Health; 2010 Aug; 13(5):592-600. PubMed ID: 20561341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program.
    Yuan Y; Iloeje U; Li H; Hay J; Yao GB
    Value Health; 2008 Mar; 11 Suppl 1():S11-22. PubMed ID: 18387054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chronic hepatitis B in Asia-Pacific countries: is the Asia-Pacific consensus statement being followed?
    Sung JJ; Amarapurkar D; Chan HL; Cheng J; Kao JH; Han KH; Piratvisuth T
    Antivir Ther; 2010; 15(4):607-16. PubMed ID: 20587854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL).
    Sarin SK; Kumar A; Almeida JA; Chawla YK; Fan ST; Garg H; de Silva HJ; Hamid SS; Jalan R; Komolmit P; Lau GK; Liu Q; Madan K; Mohamed R; Ning Q; Rahman S; Rastogi A; Riordan SM; Sakhuja P; Samuel D; Shah S; Sharma BC; Sharma P; Takikawa Y; Thapa BR; Wai CT; Yuen MF
    Hepatol Int; 2009 Mar; 3(1):269-82. PubMed ID: 19669378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.
    Kanwal F; Farid M; Martin P; Chen G; Gralnek IM; Dulai GS; Spiegel BM
    Am J Gastroenterol; 2006 Sep; 101(9):2076-89. PubMed ID: 16968510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis.
    Oliveira GL; Almeida AM; Silva AL; Brandão CM; Andrade EI; Cherchiglia ML; Acurcio Fde A
    Rev Saude Publica; 2013 Aug; 47(4):769-78; discussion 779. PubMed ID: 24346678
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.